Candel Therapeutics, Inc.
Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies for patients with cancer. Its two clinical platforms use genetically modified adenoviruses and herpes simplex viruses (HSV), with product candidates administered by injection into tumors. The company’s lead adenovirus candidate, aglatimagene, is being studied in solid tumors including prostate cancer and non-small cell lung cancer. Its lead HSV candidate, linoserpaturev, is being evaluated for recurrent high-grade glioma. Candel also uses its enLIGHTEN Discovery Platform to develop additional HSV-based candidates for solid tumors. Candel’s business is focused on developing these product candidates and seeking regulatory approval and commercialization. It owns development and commercialization rights for its programs in major markets, including the United States, Europe and Asia, and relies on third-party contract manufacturers for commercial-scale manufacturing. Candel Therapeutics is headquartered in Needham, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CADL in the last 30 days.
See all $CADL insider activity →HC Wainwright & Co. kept Candel Therapeutics at Buy but cut its price target to $18 from $23, a 21.7% reduction. The new target suggests a 114.5% upside from the Nov 12 close of $8.39. Recent analyst price targets for the company range from $13 to $25.
Canaccord Genuity kept its Buy rating on Candel Therapeutics but reduced its price target from $25 to $13, a 48% cut. This new target suggests a 54.9% upside from the Nov 12 closing price of $8.39.
Stifel cut its price target on Candel Therapeutics (CADL) to $19 from $22, citing a delay in the BLA submission timeline to mid-2027. The company is still in discussions with the FDA. Other analysts have maintained or raised their price targets, with Jefferies initiating coverage at $25. CADL shares are up 82% over the past year but are currently trading at $8.39.
Over the past 7 days, AlphAI's AI scored 15 news stories mentioning CADL (Candel Therapeutics, Inc.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 14 bearish.
Recent CADL coverage spans financial news, earnings and market movers.
HC Wainwright & Co. kept Candel Therapeutics at Buy but cut its price target to $18 from $23, a 21.7% reduction. The new target suggests a 114.5% upside from the Nov 12 close of $8.39. Recent analyst price targets for the company range from $13 to $25.
Canaccord Genuity kept its Buy rating on Candel Therapeutics but reduced its price target from $25 to $13, a 48% cut. This new target suggests a 54.9% upside from the Nov 12 closing price of $8.39.
Target cut signals lower near‑term expectations, likely pressuring the stock lower.
Regulatory setback triggers sharp sell‑off.
The news triggered a sharp sell‑off, indicating strong downward pressure.
AlphAI scores every news story that mentions CADL with an AI model for sentiment and relevance, and aggregates insider trades from Candel Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
HC Wainwright & Co. kept Candel Therapeutics at Buy but cut its price target to $18 from $23, a 21.7% reduction. The new target suggests a 114.5% upside from the Nov 12 close of $8.39. Recent analyst price targets for the company range from $13 to $25.
Canaccord Genuity kept its Buy rating on Candel Therapeutics but reduced its price target from $25 to $13, a 48% cut. This new target suggests a 54.9% upside from the Nov 12 closing price of $8.39.
Stifel cut its price target on Candel Therapeutics (CADL) to $19 from $22, citing a delay in the BLA submission timeline to mid-2027. The company is still in discussions with the FDA. Other analysts have maintained or raised their price targets, with Jefferies initiating coverage at $25. CADL shares are up 82% over the past year but are currently trading at $8.39.
Cisco (CSCO) beat earnings estimates and raised its outlook, but shares fell 2.7% premarket. Microsoft (MSFT) had service outages, shares dropped 2.5%. Applied Materials (AMAT) reported strong results, shares up 0.35%. Sellas Life Sciences (SLS) rose 15% on trial results news. Candel Therapeutics (CADL) fell 34% due to FDA delays. Kraft Heinz (KHC) shares edged up 0.7%.
Candel Therapeutics (CADL) dropped 38% in after-hours trading after updating application timing. The company initiated its Phase 3 AURORA trial for lung cancer treatment. It also amended a stock sale agreement to offer up to $50 million in common stock. Shares closed at $8.39, down 9% during regular trading. Management changes were also announced.
U.S. stock futures rose as markets attempted to recover from Nvidia's decline. Key focus areas include SELLAS Life Sciences (SLS), Microsoft (MSFT), Candel Therapeutics (CADL), and MicroStrategy (MSTR). SLS shares surged 21% after-hours due to upcoming trial results, while CADL shares dropped 38% following FDA discussions. MSTR shares fell 2% amid Bitcoin price declines. Oil prices were slightly lower, and U.S. Treasury yields climbed. Asian markets opened mixed.
Candel Therapeutics (CADL) stock fell 38% after-hours after pushing back its FDA application for prostate cancer treatment to mid-2027. The company reported $203.1M in cash, expected to last until Q2 2028. Retail traders on Stocktwits remained bullish, with some suggesting the selloff could make the stock more attractive. CADL is up 48.5% year-to-date, according to the article.
Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 12, 2026, Candel Therapeutics, Inc. (the “Company”) entered into a Second Amended and Restated Open Market Sale Agreement SM (the “2026 Sales Agreement”), with Jefferies LLC (“Jefferies”), to sell shares of the Company’s common stock, par value
Candel Therapeutics reported a Q3 2026 net loss of $21.9M, up from $11.3M a year earlier. Cash reserves were $203.1M, expected to last until Q2 2028. R&D and G&A expenses increased. The company made clinical and regulatory progress in cancer immunotherapy programs, including FDA discussions for aglatimagene in prostate cancer.
Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights • The Company is in ongoing dialogue with the FDA regarding the submission of a Biologics License Application (BLA) for aglatimagene in prostate cancer. Due to timelines
